News Category
SCHOTT Pharma's parent group's updated climate targets, now including a Scope 3 absolute reduction goal, have been validated by the Science Based Targ...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is on track with enrollment completed in the first pivotal study, positioning t...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, solidify...
Tonix Pharmaceuticals received FDA feedback supporting its adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Lyme diseas...
VERAXA Biotech advances its bispecific ADC program VXA-222 after OmniAb completes discovery work, moving toward next-phase development for precision s...
VERAXA Biotech appointed Christoph Erkel as CSO to advance its BiTAC platform for solid tumor therapies, signaling a strategic push toward clinical de...
NanoViricides announced a $3.8 million registered direct offering to fund the development of its broad-spectrum antiviral drug candidate NV-387 and ot...
VERAXA Biotech has appointed Christoph Erkel, Ph.D., as Chief Scientific Officer to lead the development of its proprietary BiTAC platform technologie...
VERAXA Biotech has obtained Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its development strategy for the lead BiTAC-TCE candida...
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on development strate...
Siegfried has appointed Eduardo Montanha as COO, effective September 1, 2026, to lead integrated operations across its global network, supporting its ...
NextPlat Corp agrees to acquire a rural Florida pharmacy for $1.5 million, aiming to expand its PharmcoRx network and introduce higher-margin services...
The completion of the analytical reference standard program for ONC010 strengthens Onco-Innovations' CMC framework, supporting regulatory and clinical...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program by partnering with ATUM, marking a key milestone toward I...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by...
VERAXA Biotech AG reports progress in its BiTAC platform with four T-cell engager programs targeting solid tumors, plans to prioritize BiTAC developme...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, aiming to advance a novel ...
The article discusses sustained deal activity in antibody-drug conjugates (ADCs) and T-cell engagers, noting that pharmaceutical companies are committ...
Ace Therapeutics announces a full-spectrum preclinical research platform for analgesic drug development, offering diverse in vivo pain models and end-...
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to address margin pressure from regulatory price adju...
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, including Phase 3 progress for HLP003 in major dep...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility and an integrated contrast drug ...
Knight Therapeutics has repaid its $60 million revolving credit facility used to acquire Paladin, funded by strong operational cash flow, maintaining ...
Voyageur Pharmaceuticals is evaluating three U.S. sites for its first fully domestic, vertically integrated iodine and barium contrast media manufactu...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has applied for a five-year advanced exploration permit at its Frances Creek barite project in British Columbia, including a ...
Voyageur Pharmaceuticals has closed a non-brokered private placement raising $5,005,278.32 to fund FDA licensing for its barium contrast products, reg...
Kairos Pharma announced plans to acquire rights to a Phase 1-ready c-MET inhibitor, advance existing clinical trials, and secure non-dilutive funding,...
Quantum BioPharma’s lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd(TM) were featured on a p...
Quantum BioPharma's clinical-stage multiple sclerosis program targeting demyelination and diversified portfolio spanning therapeutics and consumer wel...
Redwood AI Corp.'s DTC eligibility simplifies U.S. trading and its engagement with IBN aims to boost market visibility through a comprehensive investo...
Carmed Pharmaceuticals, a Turkey-based company specializing in carvacrol-based formulations, is expanding into the U.S. market, as highlighted in a Ci...
Sino Biological's new XPressMAX™ kit enables ultra-fast, cell-free protein synthesis in 3 hours, integrating with AI-driven high-throughput screening ...
NanoViricides reported progress in developing its broad-spectrum antiviral candidate NV-387, including regulatory approval for a Phase II MPox trial i...
NanoViricides has announced a $2 million registered direct offering to an institutional investor, providing capital for its clinical-stage antiviral d...
Lantern Pharma raised $4.4 million through a registered direct offering and concurrent private placement, providing capital to advance its precision o...
Tonix Pharmaceuticals (NASDAQ: TNXP) will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Confe...
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model enhances drug discovery by providing real-time molecular intelli...
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, enhances chemotherapy and immunotherapy effectiveness by disrupting DNA repair in cance...
Soligenix leverages synthetic hypericin across CTCL and psoriasis, exemplifying how platform science streamlines development and expands clinical impa...
PolyPeptide Group AG's shareholders voted overwhelmingly in favor of all board proposals at the 2026 AGM, including re-election of directors and appro...
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, highlighting leadership changes, clinical advancement of LB-100, acquisition of ...
LIXTE Biotechnology's LB-100 is the only clinical-stage PP2A inhibitor, potentially enhancing cancer therapies by sensitizing tumors to immunotherapy ...
Lonza nominates Stephen Fry, former Eli Lilly executive, to its board to leverage his expertise in organizational transformation and performance cultu...
Voyageur Pharmaceuticals advances its vertically integrated barium and iodine contrast media projects with feasibility studies and FDA submissions, ai...
Soligenix received a positive opinion from the EMA for orphan drug designation of dusquetide for Behcet's disease, unlocking incentives that may accel...
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has generated 2 million video views and 24 million impressions, highlighting the growing globa...
Oncotelic Therapeutics' inclusion in a BioMedWire editorial underscores the increasing M&A focus on de-risked, late-stage oncology and CNS assets, pos...
